Only the Oncotype DX Genomic Prostate Score® (GPS) assay addresses the unique challenges associated with Active Surveillance treatment decisions.

Decipher Prostate Biopsy® does not.

Not all prostate cancer assays are the same. The GPS assay drives immediate and actionable decisions for early-stage prostate cancer, while Decipher falls short.

For your 3+3 and 3+4 GS patients, choose the right assay to inform Active Surveillance or treatment.

Genomic Prostate Score (GPS) Decipher Prostate Biopsy
Addresses unique features of prostate cancer, including heterogeneity and multifocality1,2
Genes selected based on their performance in prostate cancer in the biopsy setting1,2
Optimized and analytically validated for small prostate biopsy tissue samples3,4 5ng of RNA 25-100ng of RNA
Extensively studies across large cohorts of GS 3+3 and 3+4 patients who are eligible for Active Surveillance1-3,5-18
Validated as a predictor of biochemical recurrence (BCR) in low- and favorable intermediate-risk patients12,17
Prospective validation data for clinical endpoint*19
Validated as a predictor of adverse pathology (AP)**1,18
Excludes pT3a+ disease from adverse pathology definition
Validated as a predictor of metastasis after radical prostatectomy (RP)17,20
Validated as a predictor of prostate cancer death after RP17,20

Oncotype DX Genomic Prostate Score (GPS) Assay

Developed and validated with genes specific to prostate cancer in the biopsy setting

Designed to guide treatment decisions in clinically low and favorable intermediate-risk prostate cancer (GS 3+3 and 3+4).
Developed with an inclusive definition of Adverse Pathology (Gleason ≥ 4+3 and/or pT3+) to aid in clinical decision-making.
Validated in patients who would be eligible for modern Active Surveillance protocols.
Optimized for small biopsy tissue specimen, minimizing test failure rates.

Over 1 million breast, colon, and prostate cancer patients have used an Oncotype DX assay to help guide their treatment decisions


*Prospective validation for adverse pathology only. **Decipher excludes pT3a+ disease from adverse pathology definition.

  1. Klein et al. Eur Urol. 2014.
  2. Erho et al. PLoS ONE. 2013.
  3. Knezevic et al. BMC Genomics. 2013.
  4. Klein et al. Urol. 2016.
  5. Badani et al. Urol Pract. 2015.
  6. Lynch et al. Am J Manag Care. 2018.
  7. Albala et al. Rev Urol. 2018.
  8. Dall’Era et al. Urol Pract. 2015.
  9. Bonham et al. USCAP 2016.
  10. Salmasi et al. J Urol. 2018.
  11. Eure et al. Urology. 2017.
  12. Cullen et al. Eur Urol. 2014.
  13. Leapman et al. PLoS ONE. 2017.
  14. Canfield et al. Rev Urol. 2018.
  15. Lin et al. ASCO GU. 2019.
  16. Kornberg et al. ASCO GU. 2019.
  17. Van Den Eeden et al. Eur Urol. 2017.
  18. Kim et al. Prostate Cancer Prostatic Dis. 2018.
  19. Eggener et al. Urology. 2019.
  20. Nguyen et al. Eur Urol. 2017.
† Decipher Prostate Biopsy is a trademark of Decipher Biosciences. Please refer to this manufacturer directly for more information.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.